Thursday, March 17, 2022
9:01 AM EST – Oncolytics Biotech Inc : Today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled “Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity,” was published in collaboration with several prestigious institutions, including the University of Leeds School of Medicine and the Institute of Cancer Research, London. Described in the paper are in vitro studies evaluating pelareorep’s effects on Natural Killer (NK) cells. Results showed pelareorep treatment led to the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity. Oncolytics Biotech Inc
(T.ONC) shares were up $0.02 at 2.
Stocks in Play: Oncolytics Biotech Inc, Thu, 17 Mar 2022 09:12:07 EST